[go: up one dir, main page]

EE200300201A - Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos - Google Patents

Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos

Info

Publication number
EE200300201A
EE200300201A EEP200300201A EEP200300201A EE200300201A EE 200300201 A EE200300201 A EE 200300201A EE P200300201 A EEP200300201 A EE P200300201A EE P200300201 A EEP200300201 A EE P200300201A EE 200300201 A EE200300201 A EE 200300201A
Authority
EE
Estonia
Prior art keywords
pyranic
self
protease inhibitors
oral dose
emulsifying composition
Prior art date
Application number
EEP200300201A
Other languages
English (en)
Inventor
Chen Shirlynn
A. Gunn Jocelyn
Original Assignee
Boehringer Ingelheim Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals, Inc. filed Critical Boehringer Ingelheim Pharmaceuticals, Inc.
Publication of EE200300201A publication Critical patent/EE200300201A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
EEP200300201A 2000-10-31 2001-10-30 Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos EE200300201A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443400P 2000-10-31 2000-10-31
PCT/US2001/048683 WO2002036110A2 (en) 2000-10-31 2001-10-30 Oral self-emulsifying formulations of pyranone protease inhibitors

Publications (1)

Publication Number Publication Date
EE200300201A true EE200300201A (et) 2003-08-15

Family

ID=22922748

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300201A EE200300201A (et) 2000-10-31 2001-10-30 Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos

Country Status (29)

Country Link
US (1) US6555558B2 (et)
EP (1) EP1333810B1 (et)
JP (1) JP4298998B2 (et)
KR (1) KR100847679B1 (et)
CN (1) CN1240437C (et)
AT (1) ATE381922T1 (et)
AU (2) AU2002230918B2 (et)
BG (1) BG107728A (et)
BR (1) BR0114969A (et)
CA (1) CA2424596C (et)
CZ (1) CZ20031407A3 (et)
DE (1) DE60132103T2 (et)
DK (1) DK1333810T3 (et)
EA (1) EA006759B1 (et)
EC (1) ECSP034572A (et)
EE (1) EE200300201A (et)
ES (1) ES2298286T3 (et)
HR (1) HRP20030339A2 (et)
HU (1) HUP0301487A2 (et)
IL (2) IL154983A0 (et)
MX (1) MXPA03003795A (et)
NO (1) NO20031909L (et)
NZ (1) NZ526169A (et)
PL (1) PL365627A1 (et)
SK (1) SK6572003A3 (et)
UA (1) UA78689C2 (et)
WO (1) WO2002036110A2 (et)
YU (1) YU32103A (et)
ZA (1) ZA200302389B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005205933B2 (en) * 2004-01-21 2010-02-18 Elanco Animal Health Ireland Limited Mitratapide oral solution
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
JP4373427B2 (ja) * 2005-11-15 2009-11-25 エフ.ホフマン−ラ ロシュ アーゲー 電気的滴下監視
WO2007061752A2 (en) * 2005-11-17 2007-05-31 Bioavailability, Inc. Biocompatible latent emulsifiers
US8277839B2 (en) * 2006-07-06 2012-10-02 Ares Trading S.A. Oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
JP2011504162A (ja) * 2007-05-23 2011-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用チプラナビルの自己乳化型製剤
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
HK1211217A1 (en) 2013-01-22 2016-05-20 霍夫曼-拉罗奇有限公司 Pharmaceutical composition with improved bioavailability
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
JP6605047B2 (ja) 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド 疼痛治療のためのセレコキシブの経口用組成物
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
EP4267132A1 (en) 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398448T1 (de) * 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
AU728626B2 (en) 1997-07-29 2001-01-11 Pharmacia & Upjohn Company Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
BR9810866B1 (pt) * 1997-07-29 2010-07-13 composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos.
WO2000025784A1 (en) * 1998-11-04 2000-05-11 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir

Also Published As

Publication number Publication date
DE60132103T2 (de) 2008-04-17
US20020115690A1 (en) 2002-08-22
KR20030048097A (ko) 2003-06-18
NZ526169A (en) 2005-12-23
EP1333810A2 (en) 2003-08-13
KR100847679B1 (ko) 2008-07-23
CA2424596C (en) 2010-06-29
ZA200302389B (en) 2004-04-23
WO2002036110A2 (en) 2002-05-10
BR0114969A (pt) 2003-12-09
DK1333810T3 (da) 2008-02-04
NO20031909D0 (no) 2003-04-29
CZ20031407A3 (cs) 2003-09-17
WO2002036110A9 (en) 2003-09-18
WO2002036110A3 (en) 2003-05-08
IL154983A0 (en) 2003-10-31
ATE381922T1 (de) 2008-01-15
IL154983A (en) 2006-12-31
EP1333810B1 (en) 2007-12-26
ES2298286T3 (es) 2008-05-16
HUP0301487A2 (hu) 2003-11-28
CN1471387A (zh) 2004-01-28
MXPA03003795A (es) 2003-08-20
BG107728A (bg) 2004-01-30
US6555558B2 (en) 2003-04-29
JP4298998B2 (ja) 2009-07-22
PL365627A1 (en) 2005-01-10
CA2424596A1 (en) 2002-05-10
SK6572003A3 (en) 2003-10-07
ECSP034572A (es) 2003-05-26
EA006759B1 (ru) 2006-04-28
CN1240437C (zh) 2006-02-08
HRP20030339A2 (en) 2005-04-30
UA78689C2 (en) 2007-04-25
YU32103A (sh) 2006-05-25
DE60132103D1 (de) 2008-02-07
NO20031909L (no) 2003-05-22
HK1060523A1 (en) 2004-08-13
JP2004512362A (ja) 2004-04-22
EA200300481A1 (ru) 2003-10-30
AU3091802A (en) 2002-05-15
AU2002230918B2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
EE200300201A (et) Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
HUP0400327A3 (en) Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use
KR100984939B9 (ko) 발사르탄 및 nep 저해제를 포함하는 제약학적 조성물
EE05020B1 (et) Glburiidi ravimkoostis
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
CY2004011I1 (el) Aσυμμετρη συνθεση της πρεγαβαλινης
DK1252293T3 (da) Kilde til levervæv
PT1253932E (pt) Composicoes farmaceuticas de toxina botulinica
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20001750L (fi) Farmaseuttisia koostumuksia
DK1373259T3 (da) Pyridazinonaldosereduktaseinhibitorer
EE200200530A (et) Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
ITMI20010748A0 (it) Composizioni farmaceutiche
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
HUP0302226A3 (en) Substituted pyrrolopyridinone dervatives useful as phosphodiesterse inhibitors, their intermediates and pharmaceutical compositions containing the compounds
IL166108A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
HUP0400328A3 (en) Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them
DK1132570T3 (da) Sammensætninger til syrebehandling af borebrönde
PL367128A1 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
IL166054A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
NO20023956L (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon